PROTAC

Three blocks displaying from left to right a person a handshake and another person

Biotech

Novartis pays $150M for Arvinas' prostate tumor protein degrader

The deal, which is worth up to $1.01 billion in milestones, will give Novartis global rights to a degrader of wild-type and mutant androgen receptor.

Nick Paul Taylor Apr 11, 2024 8:04am

Arvinas a PROTAC-ubiquitination complex

Arvinas advances anti-resistance cancer drug on sign of efficacy

Jun 8, 2023 9:30am